Daniela Dottore Stagna
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Daniela Dottore Stagna has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Antonia Pascarella
Department of Pediatrics, Santobono-Pausilipon Children's Hospital, Naples, Italy
1 shared publication - Chiara De Falco
CEINGE Biotecnologie Avanzate Franco Salvatore (Italy), Naples, Italy; Department of Molecular Medicine and Medical Biotechnologies, University of Naples Federico II, Naples, Italy, Italy
1 shared publication - Cristina Mazzaccara
Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy
1 shared publication - Dario Iafusco
Regional Centre for Pediatric Diabetes, Department of Pediatrics, University of Campania “Luigi Vanvitelli”, Napoli, Italy, Italy
1 shared publication - Enza Mozzillo
Department of Translational Medical Science, Section of Pediatrics, Regional Center of Pediatric Diabetes, Federico II University of Naples, Naples, Italy
1 shared publication - Fabiana Uomo
Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy
1 shared publication
Latest Publications
- Open Access
- 19 November 2026
- Published by MDPI AG in Preprints.org
Improved Diagnostic Yield in Mitochondrial Diseases: A Single-Center Experience Following the Validation and Clinical Implementation of a Joint MITO-NUCLEAR Next-Generation Sequencing Panel
Background/Objectives: Mitochondrial diseases (MDs) are heterogeneous genetic disorders caused by oxidative phosphorylation impairment, governed by both mitochondrial DNA (mtDNA) and nuclear DNA (nDNA). Traditional multi-step diagnostic strategies, involving mtDNA long-range PCR and screening of a limited set of nuclear genes, often leave many patients without a molecular diagnosis. This study evaluates the clinical implementation of a single-step MITO-NUCLEAR Next-Generation (NGS) panel (whole mtDNA and 254 nuclear genes), previously developed and validated by our group. Methods: Buccal swab DNA from 70 patients with suspected MDs was sequenced using an optimized probe dilution ratio (1:500, mtDNA: nDNA), achieving mean depths of ~10,000× (mtDNA) and 110× (nDNA). Variants were classified according to ACMG/AMP guidelines and their mtDNA-specific specifications. Results: Ninety unique variants were identified (86.7% nuclear). A definitive molecular diagnosis was reached in 17% of patients, compared with 5.7% for mtDNA analysis alone: four primary mtDNA defects (MT-TS1, MT-CYB, MT-TL1, MT-ATP6), two nuclear-encoded mitochondrial disorders (ECHS1, FH) and six non-mitochondrial phenocopies (WFS1, ATP7B, G6PC1, ABCA4, KIF1A). A possible diagnosis was reached in 20% of patients, 46% were carriers of monoallelic variants in recessive genes, and 17% were negative. Conclusions: Simultaneous MITO-NUCLEAR NGS testing significantly increases diagnostic yield over single-genome screening. This single-step targeted panel offers a fast and efficient tool that facilitates variant identification across both genomes, supporting accurate clinical management and timely familial genetic counseling.
- 19 November 2026
- Published by MDPI AG in Preprints.org
Open AccessImproved Diagnostic Yield in Mitochondrial Diseases: A Single-Center Experience Following the Validation and Clinical Implementation of a Joint MITO-NUCLEAR Next-Generation Sequencing Panel
Background/Objectives: Mitochondrial diseases (MDs) are heterogeneous genetic disorders caused by oxidative phosphorylation impairment, governed by both mitochondrial DNA (mtDNA) and nuclear DNA (nDNA). Traditional multi-step diagnostic strategies, involving mtDNA long-range PCR and screening of a limited set of nuclear genes, often leave many patients without a molecular diagnosis. This study evaluates the clinical implementation of a single-step MITO-NUCLEAR Next-Generation (NGS) panel (whole mtDNA and 254 nuclear genes), previously developed and validated by our group. Methods: Buccal swab DNA from 70 patients with suspected MDs was sequenced using an optimized probe dilution ratio (1:500, mtDNA: nDNA), achieving mean depths of ~10,000× (mtDNA) and 110× (nDNA). Variants were classified according to ACMG/AMP guidelines and their mtDNA-specific specifications. Results: Ninety unique variants were identified (86.7% nuclear). A definitive molecular diagnosis was reached in 17% of patients, compared with 5.7% for mtDNA analysis alone: four primary mtDNA defects (MT-TS1, MT-CYB, MT-TL1, MT-ATP6), two nuclear-encoded mitochondrial disorders (ECHS1, FH) and six non-mitochondrial phenocopies (WFS1, ATP7B, G6PC1, ABCA4, KIF1A). A possible diagnosis was reached in 20% of patients, 46% were carriers of monoallelic variants in recessive genes, and 17% were negative. Conclusions: Simultaneous MITO-NUCLEAR NGS testing significantly increases diagnostic yield over single-genome screening. This single-step targeted panel offers a fast and efficient tool that facilitates variant identification across both genomes, supporting accurate clinical management and timely familial genetic counseling.